Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

What It Covers

Viswa Colluru, founder and CEO of Envita, describes how he built a Boulder-based natural product drug discovery company from $55,000 in personal savings to a $1 billion valuation with $517 million raised, three candidates in clinical trials, and a platform that produces development candidates 4x faster than industry average with an 11x higher success rate.

Key Questions Answered

• •Contrarian timing strategy: Envita raised its seed round during the March 2020 Sequoia "black swan" memo period, when most founders assumed venture capital had frozen. By accelerating spend and generating data while competitors retreated, Colluru secured multiple term sheets. Investors with a technology bent viewed the contrarian natural products thesis as a feature, not a flaw, since outlier returns require unexpected approaches.
• •R&D efficiency benchmark: Envita reaches a development candidate in 12–14 months using only 80–120 compounds per program, versus the industry norm of roughly 4x longer timelines and 3x more compounds synthesized. The efficiency stems from natural molecules arriving pre-optimized from living systems, with 14 of 15 leads passing early exploratory toxicity studies before formal development candidate nomination.
• •Natural product chemistry as competitive moat: Because natural product molecules have complex structures with only 1–3 accessible carbons for modification, patent-busting by competitors requires far fewer degrees of freedom than with conventional synthetic compounds. Colluru argues this makes Envita's pipeline structurally resistant to rapid generic replication, particularly from high-volume synthesis programs, without any deliberate design for that outcome.
• •Mass spectrometry plus transformer models: Envita built structure-prediction capability by applying large language model transformer architectures to mass spectrometry fragmentation data. The model treats spectral peaks the way LLMs treat words — context-dependent attention predicts missing fragments and infers chemical structure without requiring individual compound purification. This approach, developed in 2021, now processes thousands of compounds from a plant sample in roughly 20 minutes.
• •Phase 1b efficacy signal for ENv294: In a phase 1b atopic dermatitis trial, all nine enrolled patients responded to ENv294, an oral once-daily small molecule with an undisclosed first-in-class mechanism acting on a previously undrugged protein complex. The trial was terminated early due to the extent of efficacy observed. Clinical remission exceeded 85% disease reduction within four weeks, with a safety profile Colluru describes as the most benign seen across the program.
• •Old-idea framework for drug discovery: Colluru applies a deliberate heuristic: pursue scientific ideas that peaked in excitement, entered a trough of disillusionment, and remain unfinished. He cites immunotherapy, statins, artemisinin, and natural product chemistry as examples. Problems in this category tend to have well-defined boundary conditions and documented bottlenecks from prior failed attempts, making them more tractable than genuinely novel hypotheses while remaining underfunded relative to their potential.